A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects

Trial Profile

A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) in Healthy Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2015

At a glance

  • Drugs Raxibacumab (Primary)
  • Indications Anthrax; Bacterial infections
  • Focus Adverse reactions; Registrational
  • Sponsors Human Genome Sciences
  • Most Recent Events

    • 17 Dec 2012 Results from this trial supported US FDA approval of raxibacumab for inhalational anthrax
    • 21 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top